Literature DB >> 28375456

Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy.

Jörn-Sven Kühl1, Felipe Suarez2, Godfrey T Gillett3, Philipp G Hemmati4, John A Snowden5, Michael Stadler6, Giang L Vuong4, Patrick Aubourg7, Wolfgang Köhler1, Renate Arnold4.   

Abstract

The adult cerebral inflammatory form of X-linked adrenoleukodystrophy is a rapidly progressive neurodegenerative disease, as devastating as childhood cerebral adrenoleukodystrophy. Allogeneic haematopoietic stem cell transplantation has been demonstrated to provide long-term neurological benefits for boys with the childhood cerebral form, but results in adults are sparse and inconclusive. We analysed data from 14 adult males with adult cerebral adrenoleukodystrophy treated with allogeneic haematopoietic stem cell transplantation on a compassionate basis in four European centres. All presented with cerebral demyelinating lesions and gadolinium enhancement. Median age at diagnosis of adult cerebral adrenoleukodystrophy was 33 years (range 21-48 years). In addition to cerebral inflammation, five patients had established severe motor disability from adrenomyeloneuropathy affecting only the spinal cord and peripheral nerves (Expanded Disability Status Scale score ≥ 6). Eight patients survived (estimated survival 57 ± 13%) with a median follow-up of 65 months (minimum 38 months). Death was directly transplant-/infection-related (n = 3), due to primary disease progression in advanced adult cerebral adrenoleukodystrophy (n = 1), or secondary disease progression (n = 2) after transient multi-organ failure or non-engraftment. Specific complications during stem cell transplantation included deterioration of motor and bladder functions (n = 12) as well as behavioural changes (n = 8). Arrest of progressive cerebral demyelination and prevention of severe loss of neurocognition was achieved in all eight survivors, but deterioration of motor function occurred in the majority (n = 5). Limited motor dysfunction (Expanded Disability Status Scale score < 6) prior to transplantation was associated with significantly improved survival [78 ± 14% (n = 9) versus 20 ± 18%(n = 5); P < 0.05] and maintenance of ambulation (Expanded Disability Status Scale score < 7) post-transplant (78% versus 0%; P = 0.021). In contrast, bilateral involvement of the internal capsule on brain MRI was associated with poorer survival [20 ± 18% (n = 5) versus 78 ± 14% (n = 9); P < 0.05]. This study is the first to support the feasibility, complications and potential long-term neurological benefit of allogeneic haematopoietic stem cell transplantation in adult cerebral adrenoleukodystrophy. Further studies are warranted to attempt to improve outcomes through patient selection and optimization of transplantation protocols.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  X-linked adrenoleukodystrophy; adult cerebral form; brain MRI; haematopoietic stem cell transplantation; long-term outcome

Mesh:

Year:  2017        PMID: 28375456     DOI: 10.1093/brain/awx016

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  17 in total

Review 1.  The Landscape of Hematopoietic Stem Cell Transplant and Gene Therapy for X-Linked Adrenoleukodystrophy.

Authors:  Eric J Mallack; Bela Turk; Helena Yan; Florian S Eichler
Journal:  Curr Treat Options Neurol       Date:  2019-11-25       Impact factor: 3.598

Review 2.  Clinical application of next-generation sequencing to the practice of neurology.

Authors:  Jessica Rexach; Hane Lee; Julian A Martinez-Agosto; Andrea H Németh; Brent L Fogel
Journal:  Lancet Neurol       Date:  2019-05       Impact factor: 44.182

Review 3.  The clinical spectrum of X-linked adrenoleukodystrophy: from Addison's-only in men to middle-age neurologic manifestations in women.

Authors:  Lúcia Fadiga; Miguel Melo; Joana Saraiva; Isabel Paiva
Journal:  Hormones (Athens)       Date:  2021-10-15       Impact factor: 2.885

4.  Presymptomatic Lesion in Childhood Cerebral Adrenoleukodystrophy: Timing and Treatment.

Authors:  Eric James Mallack; Keith P Van Haren; Anna Torrey; Stephanie van de Stadt; Marc Engelen; Gerald V Raymond; Ali Fatemi; Florian S Eichler
Journal:  Neurology       Date:  2022-05-24       Impact factor: 11.800

Review 5.  Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Authors:  Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida
Journal:  J Inherit Metab Dis       Date:  2018-02-01       Impact factor: 4.982

Review 6.  Adulthood leukodystrophies.

Authors:  Wolfgang Köhler; Julian Curiel; Adeline Vanderver
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

7.  The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance: A worm model for adrenoleukodystrophy.

Authors:  Andrea Coppa; Sanjib Guha; Stéphane Fourcade; Janani Parameswaran; Montserrat Ruiz; Ann B Moser; Agatha Schlüter; Michael P Murphy; Jose Miguel Lizcano; Antonio Miranda-Vizuete; Esther Dalfó; Aurora Pujol
Journal:  Free Radic Biol Med       Date:  2020-02-01       Impact factor: 7.376

8.  Laboratory diagnosis of disorders of peroxisomal biogenesis and function: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Irene De Biase; Silvia Tortorelli; Lisa Kratz; Steven J Steinberg; Kristina Cusmano-Ozog; Nancy Braverman
Journal:  Genet Med       Date:  2019-12-11       Impact factor: 8.822

9.  A Novel Variant in ABCD1 Gene Presenting as Adolescent-Onset Atypical Adrenomyeloneuropathy With Spastic Ataxia.

Authors:  Yanxing Chen; Jianfang Zhang; Jianwen Wang; Kang Wang
Journal:  Front Neurol       Date:  2018-04-23       Impact factor: 4.003

10.  Brain-sparing cord blood transplantation for the borderline stage of adrenoleukodystrophy.

Authors:  Yutaro Yada; Michiko Torio; Yuhki Koga; Fumiya Yamashita; Takuya Ichimura; Katsuhide Eguchi; Masataka Ishimura; Yuichi Mushimoto; Akio Hiwatashi; Momoko Sasazuki; Ryutaro Kira; Yasunari Sakai; Shouichi Ohga
Journal:  Mol Genet Metab Rep       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.